Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
暂无分享,去创建一个
P. Calabrò | P. Golino | Mario Crisci | V. Russo | A. Rago | G. Nigro | A. Papa | A. D'onofrio | R. Proietti | E. Attena | C. Rainone | A. D’Onofrio
[1] A. Camm,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.
[2] A. Camm,et al. Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT‐AF (The internAtionaL stENT – Atrial Fibrillation study) multicenter registry , 2018, Clinical cardiology.
[3] L. Bonello,et al. Dabigatran versus vitamin k antagonist: an observational across‐cohort comparison in acute coronary syndrome patients with atrial fibrillation , 2018, Journal of thrombosis and haemostasis : JTH.
[4] C. Bancone,et al. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience , 2018, Seminars in Thrombosis and Hemostasis.
[5] P. Golino,et al. Use of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review , 2017, Seminars in Thrombosis and Hemostasis.
[6] P. Golino,et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study , 2018, Journal of Thrombosis and Thrombolysis.
[7] V. Russo,et al. The clinical performance of dabigatran in the Italian real-life experience. , 2017, Journal of Cardiovascular Medicine.
[8] Deepak L. Bhatt,et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.
[9] P. Calabrò,et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence , 2017, Therapeutic advances in drug safety.
[10] P. Calabrò,et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. , 2016, International journal of cardiology.
[11] G. Lip,et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.
[12] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[13] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[14] P. Calabrò,et al. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. , 2015, European review for medical and pharmacological sciences.
[15] D. Angiolillo,et al. Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions , 2014, Circulation. Cardiovascular interventions.
[16] S. Yusuf,et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.
[17] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[18] L. Køber,et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study , 2012, Circulation.
[19] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[20] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[21] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[22] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[23] Jeroen J. Bax,et al. Universal definition of myocardial infarction. , 2007 .
[24] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[25] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[26] P. H. Beadle,et al. Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study , 2002 .